ArticleMedical oncology (Northwood, London, England)2022

Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models.

Salvador Guardiola et al.PubMed ↗Publisher ↗

No numbers read from the abstract.